Contact
searchSearch
HMP Global
Login

Prostate Cancer Specialty Channel

Sagar Patel, MD
Videos
Leuprolide Drives Higher Coronary Plaque Growth Among Patients With Prostate Cancer
12/23/2025
Sagar Patel, MD
Sagar Patel, MD, discusses updated results from the REVELUTION trial which showed that leuprolide leads to significantly greater coronary plaque progression than relugolix for patients with prostate cancer.
Sagar Patel, MD, discusses updated results from the REVELUTION trial which showed that leuprolide leads to significantly greater coronary plaque progression than relugolix for patients with prostate cancer.
Sagar Patel, MD, discusses...
12/23/2025
Oncology
FDA Approval
FDA Approves Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
12/17/2025
Stephanie Holland
Based on results from the TRITON3 study, the FDA granted approval to rucaparib for previously treated patients with deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.
Based on results from the TRITON3 study, the FDA granted approval to rucaparib for previously treated patients with deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.
Based on results from the...
12/17/2025
Oncology
News
Leuprolide Drives Significantly Higher Coronary Plaque Growth vs Relugolix in Patients With Prostate Cancer
12/16/2025
Stephanie Holland
Updated results from the REVELUTION trial show that androgen deprivation therapy with leuprolide leads to significantly greater coronary plaque progression than relugolix in patients with prostate cancer.
Updated results from the REVELUTION trial show that androgen deprivation therapy with leuprolide leads to significantly greater coronary plaque progression than relugolix in patients with prostate cancer.
Updated results from the...
12/16/2025
Oncology
News
177Lu-PSMA-617 Added to Standard of Care Improves Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
10/19/2025
Stephanie Holland
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to...
10/19/2025
Radiopharmaceutical Education Institute
From Radiopharmaceutical Education Institute
News
Cabozantinib Plus Atezolizumab Demonstrates Promise Among Patients With Metastatic Castration-Resistant Prostate Cancer and Soft-Tissue Metastases
08/19/2025
Stephanie Holland
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the...
08/19/2025
Oncology
Nick James, MD, PhD
Conference Coverage
Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer
08/12/2025
Nicholas James, MD
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses...
08/12/2025
Oncology
News
NRG1 May Predict Incidence of CRPC Among Patients With Prostate Cancer
08/05/2025
Allison Casey
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may...
08/05/2025
Oncology
FDA Approval
FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer
06/03/2025
Stephanie Holland
Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.
Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.
Based on results from the...
06/03/2025
Oncology
Conference Coverage
Lower-Dose Abiraterone Non-Inferior to Standard Dose for Metastatic Castration-Resistant Prostate Cancer
06/02/2025
Emily Estrada
A phase 3 non-inferiority trial showed lower-dose abiraterone acetate demonstrates comparable efficacy and safety to standard dosing for the treatment of metastatic castration-resistant prostate cancer.
A phase 3 non-inferiority trial showed lower-dose abiraterone acetate demonstrates comparable efficacy and safety to standard dosing for the treatment of metastatic castration-resistant prostate cancer.
A phase 3 non-inferiority trial...
06/02/2025
Oncology
News
Addition of Pembrolizumab Fails to Improve Outcomes for Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
05/28/2025
Stephanie Holland
Results from the phase 3 KEYNOTE-641 study demonstrated that the addition of pembrolizumab to enzalutamide did not improve outcomes among chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Results from the phase 3 KEYNOTE-641 study demonstrated that the addition of pembrolizumab to enzalutamide did not improve outcomes among chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Results from the phase 3...
05/28/2025
Oncology
News
Pembrolizumab Plus Enzalutamide and Androgen Deprivation Therapy Fails to Improve Survival for Patients With Metastatic Hormone-Sensitive Prostate Cancer
05/20/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-991 study, pembrolizumab plus enzalutamide and continuous androgen deprivation therapy did not improve survival results among patients with metastatic hormone-sensitive prostate cancer.
According to results from the phase 3 KEYNOTE-991 study, pembrolizumab plus enzalutamide and continuous androgen deprivation therapy did not improve survival results among patients with metastatic hormone-sensitive prostate cancer.
According to results from the...
05/20/2025
Oncology

News

FDA Approval
FDA Approves Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
12/17/2025
Stephanie Holland
Based on results from the TRITON3 study, the FDA granted approval to rucaparib for previously treated patients with deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.
Based on results from the TRITON3 study, the FDA granted approval to rucaparib for previously treated patients with deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.
Based on results from the...
12/17/2025
Oncology
News
Leuprolide Drives Significantly Higher Coronary Plaque Growth vs Relugolix in Patients With Prostate Cancer
12/16/2025
Stephanie Holland
Updated results from the REVELUTION trial show that androgen deprivation therapy with leuprolide leads to significantly greater coronary plaque progression than relugolix in patients with prostate cancer.
Updated results from the REVELUTION trial show that androgen deprivation therapy with leuprolide leads to significantly greater coronary plaque progression than relugolix in patients with prostate cancer.
Updated results from the...
12/16/2025
Oncology
News
177Lu-PSMA-617 Added to Standard of Care Improves Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
10/19/2025
Stephanie Holland
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to...
10/19/2025
Radiopharmaceutical Education Institute
News
Cabozantinib Plus Atezolizumab Demonstrates Promise Among Patients With Metastatic Castration-Resistant Prostate Cancer and Soft-Tissue Metastases
08/19/2025
Stephanie Holland
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the...
08/19/2025
Oncology
Nick James, MD, PhD
Conference Coverage
Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer
08/12/2025
Nicholas James, MD
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses...
08/12/2025
Oncology
News
NRG1 May Predict Incidence of CRPC Among Patients With Prostate Cancer
08/05/2025
Allison Casey
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may...
08/05/2025
Oncology
FDA Approval
FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer
06/03/2025
Stephanie Holland
Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.
Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.
Based on results from the...
06/03/2025
Oncology
Conference Coverage
Lower-Dose Abiraterone Non-Inferior to Standard Dose for Metastatic Castration-Resistant Prostate Cancer
06/02/2025
Emily Estrada
A phase 3 non-inferiority trial showed lower-dose abiraterone acetate demonstrates comparable efficacy and safety to standard dosing for the treatment of metastatic castration-resistant prostate cancer.
A phase 3 non-inferiority trial showed lower-dose abiraterone acetate demonstrates comparable efficacy and safety to standard dosing for the treatment of metastatic castration-resistant prostate cancer.
A phase 3 non-inferiority trial...
06/02/2025
Oncology
News
Addition of Pembrolizumab Fails to Improve Outcomes for Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
05/28/2025
Stephanie Holland
Results from the phase 3 KEYNOTE-641 study demonstrated that the addition of pembrolizumab to enzalutamide did not improve outcomes among chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Results from the phase 3 KEYNOTE-641 study demonstrated that the addition of pembrolizumab to enzalutamide did not improve outcomes among chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Results from the phase 3...
05/28/2025
Oncology
News
Pembrolizumab Plus Enzalutamide and Androgen Deprivation Therapy Fails to Improve Survival for Patients With Metastatic Hormone-Sensitive Prostate Cancer
05/20/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-991 study, pembrolizumab plus enzalutamide and continuous androgen deprivation therapy did not improve survival results among patients with metastatic hormone-sensitive prostate cancer.
According to results from the phase 3 KEYNOTE-991 study, pembrolizumab plus enzalutamide and continuous androgen deprivation therapy did not improve survival results among patients with metastatic hormone-sensitive prostate cancer.
According to results from the...
05/20/2025
Oncology

Interactive Features

Quiz
Improving Detection of Clinically Significant Prostate Cancer
01/15/2024
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the...
01/15/2024
Oncology
Quiz
Adjuvant Radiotherapy Following Radical Prostatectomy
11/13/2023
Allison Casey
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the...
11/13/2023
Oncology
Quiz
Biweekly vs Triweekly Cabazitaxel for Patients With Metastatic Castration-Resistant Prostate Cancer
11/10/2023
Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Quiz
Adaptive 177Lu-PSMA-617 Dosing in the ENZA-p Trial
11/10/2023
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Quiz
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
11/02/2022
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
True or False: A study found...
11/02/2022
Oncology
Quiz
Quiz: Enzalutamide Plus Testosterone Suppression for Metastatic Hormone-Sensitive Prostate Cancer
09/02/2022
In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...
In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...
In the ENZAMET trial evaluating...
09/02/2022
Oncology
Quiz
Quiz: Does the Polaris Test Prognosticate Risk of Metastasis in Prostate Cancer?
07/21/2022
Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?
Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?
Quiz: The commercially-available...
07/21/2022
Oncology
Test Your Knowledge
Quiz: Can the Prolaris Test Estimate Metastasis in Prostate Cancer?
09/02/2021
True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.
True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.
True or false: For patients with...
09/02/2021
Oncology
Test Your Knowledge
Quiz: Can Large Antibodies Target PSMA Expression During mCRPC Treatment?
07/29/2021
True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.
True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.
True or False: Since small...
07/29/2021
Oncology
Test Your Knowledge
Quiz: Which Approach Offers Improved Safety with J591 for mCRPC?
07/29/2021
Which treatment approach demonstrates greater safety outcomes when using a full-length antibody to target PSMA, particularly with actinium J591, for patients with mCRPC?
Which treatment approach demonstrates greater safety outcomes when using a full-length antibody to target PSMA, particularly with actinium J591, for patients with mCRPC?
Which treatment approach...
07/29/2021
Oncology

Recent News

FDA Approval
FDA Approves Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
12/17/2025
Stephanie Holland
Based on results from the TRITON3 study, the FDA granted approval to rucaparib for previously treated patients with deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.
Based on results from the TRITON3 study, the FDA granted approval to rucaparib for previously treated patients with deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.
Based on results from the...
12/17/2025
Oncology
News
Leuprolide Drives Significantly Higher Coronary Plaque Growth vs Relugolix in Patients With Prostate Cancer
12/16/2025
Stephanie Holland
Updated results from the REVELUTION trial show that androgen deprivation therapy with leuprolide leads to significantly greater coronary plaque progression than relugolix in patients with prostate cancer.
Updated results from the REVELUTION trial show that androgen deprivation therapy with leuprolide leads to significantly greater coronary plaque progression than relugolix in patients with prostate cancer.
Updated results from the...
12/16/2025
Oncology
News
177Lu-PSMA-617 Added to Standard of Care Improves Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
10/19/2025
Stephanie Holland
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to...
10/19/2025
Radiopharmaceutical Education Institute
News
Cabozantinib Plus Atezolizumab Demonstrates Promise Among Patients With Metastatic Castration-Resistant Prostate Cancer and Soft-Tissue Metastases
08/19/2025
Stephanie Holland
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the...
08/19/2025
Oncology
News
NRG1 May Predict Incidence of CRPC Among Patients With Prostate Cancer
08/05/2025
Allison Casey
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may...
08/05/2025
Oncology
FDA Approval
FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer
06/03/2025
Stephanie Holland
Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.
Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.
Based on results from the...
06/03/2025
Oncology
Conference Coverage
Lower-Dose Abiraterone Non-Inferior to Standard Dose for Metastatic Castration-Resistant Prostate Cancer
06/02/2025
Emily Estrada
A phase 3 non-inferiority trial showed lower-dose abiraterone acetate demonstrates comparable efficacy and safety to standard dosing for the treatment of metastatic castration-resistant prostate cancer.
A phase 3 non-inferiority trial showed lower-dose abiraterone acetate demonstrates comparable efficacy and safety to standard dosing for the treatment of metastatic castration-resistant prostate cancer.
A phase 3 non-inferiority trial...
06/02/2025
Oncology
News
Addition of Pembrolizumab Fails to Improve Outcomes for Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
05/28/2025
Stephanie Holland
Results from the phase 3 KEYNOTE-641 study demonstrated that the addition of pembrolizumab to enzalutamide did not improve outcomes among chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Results from the phase 3 KEYNOTE-641 study demonstrated that the addition of pembrolizumab to enzalutamide did not improve outcomes among chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Results from the phase 3...
05/28/2025
Oncology
News
Pembrolizumab Plus Enzalutamide and Androgen Deprivation Therapy Fails to Improve Survival for Patients With Metastatic Hormone-Sensitive Prostate Cancer
05/20/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-991 study, pembrolizumab plus enzalutamide and continuous androgen deprivation therapy did not improve survival results among patients with metastatic hormone-sensitive prostate cancer.
According to results from the phase 3 KEYNOTE-991 study, pembrolizumab plus enzalutamide and continuous androgen deprivation therapy did not improve survival results among patients with metastatic hormone-sensitive prostate cancer.
According to results from the...
05/20/2025
Oncology
News
Adding Pembrolizumab to Docetaxel Does Not Improve Survival Outcomes for Metastatic Castration-Resistant Prostate Cancer
04/21/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the...
04/21/2025
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use